Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effects of TMS-tACS on Central Autonomic Coupling and Cognition

11. november 2026 opdateret af: Xidian University

Modulatory Effects of Combined TMS-tACS Stimulation on Central Autonomic Coupling and Cognitive Function

This study investigates the effects of combined transcranial magnetic stimulation (TMS) and transcranial alternating current stimulation (tACS) on cognitive function and brain-visceral coupling in healthy adults, while exploring the underlying neural mechanisms. Participants will undergo four different neuromodulation conditions, including TMS stimulation, tACS stimulation, combined TMS-tACS stimulation, and sham stimulation. The order of stimulation sessions will be counterbalanced using a randomized Latin square design. During each experimental session, researchers will simultaneously record participants' electroencephalography (EEG), electrocardiography (ECG), respiratory, and gastric signals before and after stimulation, and evaluate cognitive performance through behavioral tasks following stimulation. The primary objective of this study is to investigate how different neuromodulation patterns influence brain-visceral coupling and cognitive function, and to further examine the relationship between changes in central-autonomic interactions and cognitive performance. The findings may provide experimental evidence for understanding the neural mechanisms underlying cognitive regulation and optimizing future non-invasive neuromodulation approaches.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is an exploratory, randomized, single-blind, sham-controlled, within-subject crossover study designed to investigate the regulatory effects of combined transcranial magnetic stimulation (TMS) and transcranial alternating current stimulation (tACS) on cognitive function and brain-visceral coupling, as well as the underlying neural mechanisms in healthy adults.

Participants will undergo four experimental stimulation conditions, including TMS stimulation, tACS stimulation, combined TMS-tACS stimulation, and sham stimulation. The order of the four stimulation conditions will be balanced using a Latin square design to minimize potential sequence effects, learning effects, and carry-over effects between conditions. A minimum interval of one week will be maintained between experimental sessions. Before stimulation, participants will undergo safety screening and resting motor threshold (RMT) assessment, which will be used to determine individualized stimulation parameters.

During each experimental session, researchers will simultaneously record multimodal physiological signals, including electroencephalography (EEG), electrocardiography (ECG), respiratory signals, and gastric electrical activity, before and after stimulation. Following the intervention, participants will complete cognitive assessment tasks to evaluate changes in cognitive performance induced by different neuromodulation conditions. Participants will not be informed of the specific stimulation condition received in each session to ensure the objectivity and scientific validity of the study.

Primary outcome measures include: brain-visceral coupling metrics, which characterize bidirectional interactions between central neural activity and autonomic physiological rhythms; heartbeat-evoked potentials (HEP), an EEG component time-locked to ECG R-peaks that reflects cortical processing of cardiac afferent information and interoceptive function; heart rate variability (HRV), which reflects autonomic nervous system regulation; and EEG oscillatory activity, which evaluates changes in neural rhythmic dynamics induced by stimulation. Cognitive performance measures will also be collected to investigate the relationship between alterations in brain-visceral coupling and cognitive function.

The primary objective of this study is to systematically examine how different neuromodulation patterns, including TMS, tACS, and combined TMS-tACS stimulation, influence brain-visceral coupling and cognitive function, and to further explore the association between central-autonomic interactions and cognitive performance. The findings may provide experimental evidence for understanding the mechanisms of brain-body interaction and optimizing future non-invasive neuromodulation approaches for cognitive enhancement.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Shaanxi
      • Xi'an, Shaanxi, Kina, 71000
        • Rekruttering
        • Xidian University
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 55 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

  1. Age between 18 and 55 years.
  2. Right-handed individuals.
  3. Body mass index (BMI) between 18 and 24.
  4. No contraindications to transcranial magnetic stimulation (TMS).
  5. No history of clinically significant cardiac disease.
  6. No gastrointestinal disorders.
  7. No respiratory system disorders.
  8. No ear-related diseases.
  9. Voluntary participation and provision of written informed consent.
  10. No participation in other neuromodulation studies within the past month.
  11. Ability to understand the experimental procedures and complete cognitive tasks as required.

Exclusion Criteria

  1. History of epilepsy, traumatic brain injury, severe headache, brain surgery, or other neurological disorders.
  2. History of psychiatric disorders, cognitive impairment, or recent use of medications that may affect central nervous system excitability, including sedatives, antidepressants, or stimulants.
  3. Presence of any contraindications to TMS, including metallic implants, cardiac pacemakers, implantable electronic devices, cochlear implants, or other implanted devices.
  4. Infection, inflammation, ulceration, skin lesions, allergy, reduced sensation, or structural abnormalities of the external ear or stimulation sites.
  5. History of vagus nerve injury or related surgical procedures.
  6. History of cardiovascular diseases, respiratory diseases, gastrointestinal ulcers, or other medical conditions that may affect experimental safety or study outcomes.
  7. Bilateral hand dysfunction preventing completion of experimental tasks.
  8. Current smoking, long-term substance dependence, or recent conditions that may influence study outcomes, such as severe sleep deprivation, alcohol consumption, or excessive fatigue.
  9. Recent participation in other neuromodulation-related experiments.
  10. Refusal to sign the informed consent form.
  11. Any other conditions considered unsuitable for participation by the investigators.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: TMS group

Transcranial Magnetic Stimulation (TMS) Stimulation Condition

Transcranial magnetic stimulation was applied to the dorsolateral prefrontal cortex (DLPFC), targeting the F3 site based on the international 10-20 EEG system. Repetitive transcranial magnetic stimulation (rTMS) was delivered at a frequency of 10 Hz with an intensity of 80% of the resting motor threshold (RMT). The stimulation protocol consisted of 30-second stimulation periods followed by 30-second inter-train intervals, with 15 repeated stimulation cycles and a total of 4,500 pulses. No concurrent tACS stimulation was applied during this condition.

Eksperimentel: tACS group

Transcranial Alternating Current Stimulation (tACS) Stimulation Condition

Transcranial alternating current stimulation (tACS) was applied to the dorsolateral prefrontal cortex (DLPFC), targeting the F3 site according to the international 10-20 EEG system. The stimulation intensity was set at 1 mA and continuously delivered for 15 minutes, including 5-second ramp-up and ramp-down periods. No concurrent transcranial magnetic stimulation was applied during this condition.

Eksperimentel: TMS-tACS combined stimulation group

Combined TMS-tACS Stimulation Condition

Combined transcranial magnetic stimulation and transcranial alternating current stimulation (TMS-tACS) were applied to the dorsolateral prefrontal cortex (DLPFC) targeting the F3 site according to the international 10-20 EEG system. Repetitive transcranial magnetic stimulation (rTMS) was delivered at a frequency of 10 Hz with an intensity of 80% of the resting motor threshold (RMT). The stimulation protocol consisted of 30-second stimulation periods followed by 30-second intervals, with 15 repeated stimulation cycles and a total of 4,500 pulses. Transcranial alternating current stimulation (tACS) was applied simultaneously with an intensity of 1 mA for 15 minutes, including 5-second ramp-up and ramp-down periods. During combined stimulation, TMS pulses were triggered at the peak phase of the tACS sinusoidal waveform to achieve phase-synchronized neuromodulation.

Sham-komparator: Sham stimulation group

Sham Stimulation Condition

A sham stimulation condition was applied to simulate the sensory experience of active TMS-tACS stimulation without delivering effective neuromodulation. During sham tACS, electrical current was briefly delivered at the beginning of stimulation to mimic the initial skin sensation, while sham TMS was performed using prerecorded stimulation sounds to reproduce the auditory experience associated with active stimulation. No effective magnetic or electrical stimulation was delivered.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Heart-Brain Coupling (Modulation Index)
Tidsramme: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous electroencephalography (EEG) and electrocardiography (ECG) data will be recorded. Heart-brain coupling will be quantified using the Modulation Index (MI) to assess the coupling between cardiac rhythms and cortical oscillatory activity. MI is a dimensionless index ranging from 0 to 1, with higher values indicating stronger coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Respiration-Brain Coupling (Modulation Index)
Tidsramme: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous electroencephalography (EEG) and respiratory signals will be recorded. Respiration-brain coupling will be quantified using the Modulation Index (MI) to assess the coupling between respiratory rhythms and cortical oscillatory activity. MI is a dimensionless index ranging from 0 to 1, with higher values indicating stronger coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Gastric-Brain Coupling (Modulation Index)
Tidsramme: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous electroencephalography (EEG) and electrogastrography (EGG) data will be recorded. Gastric-brain coupling will be quantified using the Modulation Index (MI) to assess the coupling between gastric electrical rhythms and cortical oscillatory activity. MI is a dimensionless index ranging from 0 to 1, with higher values indicating stronger coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Heart-Brain Coupling (Phase-Locking Value)
Tidsramme: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and ECG signals will be recorded. Heart-brain phase synchronization will be quantified using the phase-locking value (PLV), which measures the consistency of phase differences between cardiac-related rhythms and cortical oscillations. PLV ranges from 0 to 1, with higher values indicating stronger phase synchronization.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Heart-Brain Coupling (Mean Vector Length)
Tidsramme: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and ECG signals will be recorded. Heart-brain coupling will be assessed using the mean vector length (MVL), which quantifies the relationship between cardiac-related phase and cortical oscillatory amplitude. Higher MVL values indicate stronger phase-amplitude coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Respiration-Brain Coupling (Phase-Locking Value)
Tidsramme: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and respiratory signals will be recorded. Respiration-brain phase synchronization will be quantified using the phase-locking value (PLV), which measures the consistency of phase differences between respiratory rhythms and cortical oscillations. PLV ranges from 0 to 1, with higher values indicating stronger phase synchronization.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Respiration-Brain Coupling (Mean Vector Length)
Tidsramme: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and respiratory signals will be recorded. Respiration-brain coupling will be assessed using the mean vector length (MVL), which quantifies the relationship between respiratory phase and cortical oscillatory amplitude. Higher MVL values indicate stronger phase-amplitude coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Gastric-Brain Coupling (Phase-Locking Value)
Tidsramme: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and EGG signals will be recorded. Gastric-brain phase synchronization will be quantified using the phase-locking value (PLV), which measures the consistency of phase differences between gastric electrical rhythms and cortical oscillations. PLV ranges from 0 to 1, with higher values indicating stronger phase synchronization.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
Gastric-Brain Coupling (Mean Vector Length)
Tidsramme: At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.

Simultaneous EEG and EGG signals will be recorded. Gastric-brain coupling will be assessed using the mean vector length (MVL), which quantifies the relationship between gastric electrical phase and cortical oscillatory amplitude. Higher MVL values indicate stronger phase-amplitude coupling.

At baseline (before stimulation), immediately after stimulation (T0), and approximately 60 minutes after stimulation (T60), during 10-minute resting-state recordings.
N-back Working Memory Task Performance (d-prime)
Tidsramme: After each stimulation session, during the post-stimulation cognitive assessment.

Working memory performance will be assessed using the N-back task. The sensitivity index (d-prime, d') will be calculated based on the hit rate and false alarm rate using signal detection theory. Higher d-prime values indicate better working memory performance and greater ability to discriminate target from non-target stimuli.

After each stimulation session, during the post-stimulation cognitive assessment.
Visuospatial Working Memory Task Accuracy
Tidsramme: After each stimulation session, during the post-stimulation cognitive assessment.

Visuospatial working memory performance will be assessed using a visuospatial memory task. Task accuracy will be calculated as the percentage of correct responses relative to the total number of responses. Accuracy ranges from 0% to 100%, with higher values indicating better visuospatial working memory performance.

After each stimulation session, during the post-stimulation cognitive assessment.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

15. december 2026

Primær færdiggørelse (Anslået)

1. april 2027

Studieafslutning (Anslået)

1. april 2027

Datoer for studieregistrering

Først indsendt

30. oktober 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 20260803

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .